EA202192192A1 - Способ лечения или профилактики рака путем целенаправленного воздействия на внеклеточную часть кератина 14 (krt14), присутствующую на раковых клетках - Google Patents
Способ лечения или профилактики рака путем целенаправленного воздействия на внеклеточную часть кератина 14 (krt14), присутствующую на раковых клеткахInfo
- Publication number
- EA202192192A1 EA202192192A1 EA202192192A EA202192192A EA202192192A1 EA 202192192 A1 EA202192192 A1 EA 202192192A1 EA 202192192 A EA202192192 A EA 202192192A EA 202192192 A EA202192192 A EA 202192192A EA 202192192 A1 EA202192192 A1 EA 202192192A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- krt14
- cancer cells
- present
- keratin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 6
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 108010066321 Keratin-14 Proteins 0.000 title 2
- 230000002265 prevention Effects 0.000 title 1
- 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4742—Keratin; Cytokeratin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Data Mining & Analysis (AREA)
- Medical Informatics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioinformatics & Computational Biology (AREA)
Abstract
Раскрыты способы, применения и композиции для лечения или профилактики рака у субъекта-млекопитающего, включающие введение субъекту количества средства, которое нацеливается на внеклеточную часть KRT14 или ее функциональный гомолог или его вариант, присутствующий на раковых клетках, или средства, которое индуцирует продукцию антагониста внеклеточной части KRT14 или ее функционального гомолога или варианта на раковых клетках. Изобретение также распространяется на способы мониторинга и/или диагностики рака у субъекта.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019900382A AU2019900382A0 (en) | 2019-02-07 | A method of treatment and prophylaxis | |
PCT/AU2020/050106 WO2020160628A1 (en) | 2019-02-07 | 2020-02-07 | A method for the treatment or prophylaxis of cancer by targeting the extracellular portion of keratin 14 (krt14) residing on cancer cells |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202192192A1 true EA202192192A1 (ru) | 2021-11-22 |
Family
ID=71946919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202192192A EA202192192A1 (ru) | 2019-02-07 | 2020-02-07 | Способ лечения или профилактики рака путем целенаправленного воздействия на внеклеточную часть кератина 14 (krt14), присутствующую на раковых клетках |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220127341A1 (ru) |
EP (1) | EP3923984A4 (ru) |
JP (1) | JP2022520383A (ru) |
KR (1) | KR20210126057A (ru) |
CN (1) | CN113710273A (ru) |
AU (1) | AU2020219149A1 (ru) |
BR (1) | BR112021015586A2 (ru) |
CA (1) | CA3129349A1 (ru) |
EA (1) | EA202192192A1 (ru) |
IL (1) | IL285437A (ru) |
SG (1) | SG11202108642QA (ru) |
WO (1) | WO2020160628A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112007161B (zh) * | 2020-09-17 | 2022-10-21 | 山东大学齐鲁医院 | Cdca8在制备治疗卵巢癌药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100317533A1 (en) * | 2009-06-05 | 2010-12-16 | British Columbia Cancer Agency Branch | Biomarkers of cancer metastasis |
US20120190573A1 (en) * | 2009-07-27 | 2012-07-26 | The Regents Of The University Of California | Biomarker of lung cancer |
US10545133B2 (en) * | 2013-05-13 | 2020-01-28 | The Johns Hopkins University | Molecular signatures of invasive cancer subpopulations |
US11590098B2 (en) * | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
-
2020
- 2020-02-07 KR KR1020217028479A patent/KR20210126057A/ko unknown
- 2020-02-07 SG SG11202108642QA patent/SG11202108642QA/en unknown
- 2020-02-07 CN CN202080027497.XA patent/CN113710273A/zh active Pending
- 2020-02-07 CA CA3129349A patent/CA3129349A1/en active Pending
- 2020-02-07 AU AU2020219149A patent/AU2020219149A1/en active Pending
- 2020-02-07 BR BR112021015586-4A patent/BR112021015586A2/pt unknown
- 2020-02-07 US US17/429,093 patent/US20220127341A1/en active Pending
- 2020-02-07 JP JP2021546809A patent/JP2022520383A/ja active Pending
- 2020-02-07 EA EA202192192A patent/EA202192192A1/ru unknown
- 2020-02-07 EP EP20752847.2A patent/EP3923984A4/en active Pending
- 2020-02-07 WO PCT/AU2020/050106 patent/WO2020160628A1/en unknown
-
2021
- 2021-08-08 IL IL285437A patent/IL285437A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN113710273A (zh) | 2021-11-26 |
AU2020219149A1 (en) | 2021-09-02 |
US20220127341A1 (en) | 2022-04-28 |
WO2020160628A1 (en) | 2020-08-13 |
BR112021015586A2 (pt) | 2021-10-05 |
SG11202108642QA (en) | 2021-09-29 |
EP3923984A1 (en) | 2021-12-22 |
IL285437A (en) | 2021-09-30 |
KR20210126057A (ko) | 2021-10-19 |
JP2022520383A (ja) | 2022-03-30 |
CA3129349A1 (en) | 2020-08-13 |
EP3923984A4 (en) | 2023-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018528252A5 (ru) | ||
MX2019010848A (es) | Composiciones y procedimientos para el tratamiento del cancer. | |
MD3455258T2 (ro) | Metode de tratament al cancerului de piele prin administrarea unui inhibitor PD-1 | |
WO2018112446A3 (en) | Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease | |
NZ739503A (en) | A novel approach for treatment of cancer using immunomodulation | |
DE60329415D1 (de) | Pyridine zur behandlung von verletztemsäugetiernervengewebe | |
EA201891507A1 (ru) | Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе | |
MX2021013901A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
MD3341379T2 (ro) | Inhibitori ai EZH2 | |
BR112018006687A2 (pt) | prevenção, tratamento e reversão de doenças utilizando montantes terapeuticamente eficazes de ácidos graxos ativos | |
BR112018071602A2 (pt) | compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase | |
MY187552A (en) | Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions | |
MX2020012107A (es) | Composiciones y procedimientos para el tratamiento del cancer. | |
EA202090116A1 (ru) | Композиции, содержащие конъюгаты каннабиноидного аналога, и способы применения | |
MX2020010502A (es) | Agentes farmacológicos para el tratamiento de enfermedades oculares. | |
EA202192192A1 (ru) | Способ лечения или профилактики рака путем целенаправленного воздействия на внеклеточную часть кератина 14 (krt14), присутствующую на раковых клетках | |
RU2018124487A (ru) | Лечение внутрипеченочного холестаза и родственных заболеваний печени | |
MX2021007738A (es) | Derivados de (piridin-2-il)amina como inhibidores de tgf-beta r1 (alk5) para el tratamiento de cancer. | |
MX2017009963A (es) | Composición y método para el tratamiento de padecimientos de la piel. | |
EA202190057A1 (ru) | Солюбилизированные апиразы, способы и применение | |
JP2019510807A5 (ru) | ||
MX2020010606A (es) | Compuestos de pladienolida y su uso. | |
AU2017261303A1 (en) | Ophthalmic compositions | |
MX2018009125A (es) | Uso de antagonistas de prostaciclina para el tratamiento de la nocicepcion de la superficie ocular. |